Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Jan 2022| BIO162B| BCC Publishing
Sample Report

Report Highlights

The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.

Report Includes

  • 37 data tables and 55 additional tables
  • An updated review of the global market for chimeric antigen receptor (CAR) T-cell therapy with emphasis on the current research and development status
  • Analyses of the global market trends, with historic data from 2018-2020, estimates for 2021 and 2022, and projections of compound annual growth rates (CAGRs) through 2026
  • Evaluation and forecast the overall CAR T-Cell therapy market size in dollar value terms, and corresponding market share analysis by product, application, technology and region
  • Highlights of the market potential for the CAR T-cell therapy market, opportunities and trends estimating current and future demand, and impact of COVID-19 on the progress of this market
  • Assessment of current marketed drugs, including development activities, R&D activities and anticipated developments, along with a look into the patent expirations within the industry
  • Latest information on the major stakeholders of global CAR T-Cell therapy market, along with a review of their intellectual property status, product innovations, technological advancements, and research collaborations and business consolidations
  • Insight into the current competitive environment, recent mergers and acquisitions, license agreements, and company revenue share analysis of the key players involved in the development of therapeutics for CAR T-cell therapy
  • Descriptive company profiles of the leading industry players, including AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Novartis AG, F. Hoffmann-La Roche and Takeda Pharmaceutical Co., Ltd.

Report Scope

The key objectives of this study are to:

  • Review the historical development of CAR T-cell technology.
  • Discuss the principles of chimeric antigen receptor design.
  • Understand the mechanisms of action associated with CAR T-cell immunotherapy.
  • Highlight the ongoing clinical and non-clinical advancements in the field of CAR T-cell therapy.
  • Access the side effects, disadvantages and limitations of existing CAR T-cell technologies.
  • Examine the current marketed drugs, including development activities and details of patent expirations.
  • Determine the production methods for CAR T-cells.
  • Review the range of joint ventures, collaborations, license and research agreements currently focused on CAR T-cell technology.
  • Review of the regulatory requirements.
  • Review the global CAR T-cell therapy market dynamics.
  • Survey the key players involved in the development of therapeutics for CAR T-cell immunotherapy and provide company profiles.

By purchasing this study, the reader will gain:

  • An improved understanding of the current state and future of this exciting, new and innovative technology.
  • The latest information on the leading companies engaged in developing this technology, clinical trials being conducted, a review of the status of their intellectual property, product pipelines and insight into their proprietary technologies.
  • The role and influence of individual countries relating to the development of CAR T-cell therapy and the number of CAR T-cell trials in the U.S. versus China and other countries.
  • Knowledge of the market potential for the CAR T-cell therapy market and anticipated development of the market.

The analysis includes the use of charts and graphs measuring product growth and trends within the marketplace. In addition, an analysis of the incidence and mortality associated with cancers and the target market helps provide the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report.

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesPrice Member Price
Full Report: Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy353 $5,500 Free
Chapter- 1: Introduction6Free DownloadFree
Chapter- 2: Summary and Highlights6$250Free
Chapter- 3: Introduction to Chimeric Antigen Receptor (CAR) T-Cell Therapy27$497Free
Chapter- 4: Impact of COVID-19 on the Market3$55Free
Chapter- 5: Market Dynamics5$92Free
Chapter- 6: Current Production Methods, Latest Technological Advances and Future Direction19$349Free
Chapter- 7: Clinical Trials on CAR T Cells and Related Technologies46$846Free
Chapter- 8: Cancer Demographics: A Global Summary17$313Free
Chapter- 9: Global CAR T-Cell Market Analysis9$166Free
Chapter- 10: Regional Analysis6$110Free
Chapter- 11: Regulatory and Legislative Requirements34$625Free
Chapter- 12: Patent Review/New Developments56$1,030Free
Chapter- 13: Global Competitive Market Landscape6$110Free
Chapter- 14: Company Profiles59$1,085Free
Chapter- 15: Appendix A13$239Free
Chapter- 16: Appendix B4$74Free
Chapter- 17: Appendix C4$74Free
Chapter- 18: Appendix D17$313Free
Chapter- 19: Appendix E16$294Free
Published - Aug-2018| Analyst - Paul Taylor| Code - BIO162A

Report Highlights

The global market for Chimeric Antigen Receptor (CAR) T-cell therapies will grow from nearly $467.0 million in 2018 to $2.9 billion by 2023 at a compound annual growth rate (CAGR) of 44.1% for the period of 2018-2023.

Report Includes

  • 31 data tables and 41 additional tables
  • An overview of global market for current research & developments status of Chimeric Antigen Receptor (CAR) T-cell therapy
  • Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Understand market dynamics of CAR T-Cell therapy, along with the growth driving factors, restraints and future scope
  • Information on competitor initiatives, research and development status of CAR T-cell therapy
  • Comprehensive company profiles of major players in the market including, Amgen, Avacta Life Sciences Ltd., Bluebird Bio Inc., Novartis Ag, Servier Laboratories, Takeda Pharmaceuticals, and Transgene SA
Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS